Effect of orlistat on cardiovascular disease risk in obese adults

Swinburn, Boyd, Carey, D., Hills, A.P., Hooper, M., Marks, S., Proietto, J., Strauss, B.J., Sullivan, D., Welborn, T.A and Caterson, I.D 2005, Effect of orlistat on cardiovascular disease risk in obese adults, Diabetes, obesity & metabolism, vol. 7, no. 3, pp. 254-262, doi: 10.1111/j.1463-1326.2004.00467.x.

Attached Files
Name Description MIMEType Size Downloads

Title Effect of orlistat on cardiovascular disease risk in obese adults
Author(s) Swinburn, Boyd
Carey, D.
Hills, A.P.
Hooper, M.
Marks, S.
Proietto, J.
Strauss, B.J.
Sullivan, D.
Welborn, T.A
Caterson, I.D
Journal name Diabetes, obesity & metabolism
Volume number 7
Issue number 3
Start page 254
End page 262
Publisher John Wiley & Sons Ltd
Place of publication Bognor Regis, England
Publication date 2005-05
ISSN 1462-8902
Keyword(s) anti-obesity drugs
CVD risk factors
weight loss
antihypertensive agent
blood pressure measurement;
Summary Aim: The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months, in conjunction with a fat-reduced, but otherwise ad libitum, diet.

Methods: A double-blind, randomized, placebo-controlled, parallel study was performed in conjunction with a fat-reduced diet and physical activity advice for 1 year. Participants (n = 339) from eight centres in Australia and New Zealand were randomized to either orlistat (120 mg) three times daily (n = 104 women, 66 men; mean ± s.d. age = 52.0 ± 7.5 years, body mass index (BMI) = 37.6 ± 5.1 kg/m2) or placebo three times daily (n = 89 women, 80 men; age = 52.5 ± 7.4 years, BMI = 38.0 ± 4.9 kg/m2). The primary efficacy criterion was the 10-year risk of developing CVD calculated from the Framingham equation. Secondary efficacy criteria were body weight, waist circumference, blood pressure and serum concentrations of triglycerides, cholesterol (total, LDL and HDL), glucose, insulin and glycated haemoglobin and quality of life.

Results: There was no difference in the change in 10-year CVD risk between orlistat and placebo groups over 1 year. The orlistat group, however, had significant favourable changes in many of the individual CVD risk factors (total cholesterol, LDL-cholesterol, glucose, glycated haemoglobin, insulin, body weight and waist circumference) and one of the domains of quality of life measured by means of the SF-36 questionnaire (vitality), compared to the placebo group. Significant reductions in medication use for hypertension and diabetes were observed in the orlistat group, compared to those in placebo, but there were no significant differences in medication use for blood lipids.

Conclusions: Orlistat may have reduced CVD risk, as judged by the favourable changes in individual risk factors and reductions in medication use, but the method used in order to measure absolute CVD risk in this study (Framingham CVD equation) was not sensitive enough to detect the changes in this relatively low-risk group (approximately 10% of risk of a CVD event over 10 years).
Notes The definitive version may be found at www.wiley.com
Language eng
DOI 10.1111/j.1463-1326.2004.00467.x
Field of Research 111799 Public Health and Health Services not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2004, Blackwell Publishing
Persistent URL http://hdl.handle.net/10536/DRO/DU:30003360

Document type: Journal Article
Collections: Faculty of Health
School of Exercise and Nutrition Sciences
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 50 times in TR Web of Science
Scopus Citation Count Cited 56 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 1113 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 07 Jul 2008, 08:50:55 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.